The court found that administration of Enbrel falls outside the scope of the asserted claims based on the court’s interpretation of these claims to exclude extracellular methods of reducing NF-eB activity.
Harvey Berger, chairman and CEO of Ariad, said: “We are disappointed by these rulings on claim construction and non-infringment, and plan to pursue the appropriate legal action to obtain review of the rulings.”